

# The Pain Stops Here

(NAPSA)—For more than 15 million people in the U.S. with diabetes, the daily grind of glucose monitoring is a “sore subject.” Pricking sensitive fingertips every day to test blood sugar levels, and the lingering soreness that results, makes necessary testing a painful procedure. Thanks to a new meter from Abbot Laboratories, MediSense Products, the pain stops here.

The new system, called Sof-Tact, is the first available monitor to provide virtually painless, automated testing. As an alternate-site meter, Sof-Tact allows users to draw blood samples from parts of the body with fewer nerve endings like the forearm and upper arm. In clinical trials, nearly 9 out of 10 patients rated Sof-Tact as either “painless” or “much less painful” than traditional fingerstick testing. And, the meter works with just one press of a button.

To perform a test, users load a test strip and lancet inside the meter, place Sof-Tact on the desired alternate site and press the ‘start’ button. Sof-Tact automatically lances the skin, draws the required blood sample, transfers the sample to the test strip and provides a glucose reading in 20 seconds.

Tracking glucose readings is an important concern for people with diabetes. Maintaining sufficient records allows patients and their doctors to address individual needs and adjust treatments accordingly.

Sof-Tact makes recording and analyzing blood glucose readings effortless. The meter stores up to 450 results and provides average glucose readings for the last 7, 14 and 28 days on its display. Data can also be downloaded to a personal computer using optional Precision Link software for even



more efficient management.

The enhanced capabilities as well as the more convenient testing of the Sof-Tact system could potentially lead to better diabetes management. And better management can help to reduce the risk of developing diabetes-related complications such as blindness, heart disease, stroke, high blood pressure, kidney failure and amputations. Each year 180,000 Americans die from diabetes related complications. And, in what the government calls dramatic evidence of an unfolding epidemic, the number of Americans with diabetes is expected to increase from 15 million to 22 million by 2025.

Sof-Tact is the world's first automated and integrated blood glucose management system. People living with diabetes and their caregivers—from those who rely on the use of their fingers, to patients with poor vision or limited motor skills, to children and their parents—will find Sof-Tact to be a breakthrough in technology that provides virtually pain-free, more convenient blood glucose testing.

To purchase or learn more about Sof-Tact, call toll-free 1-866-SOF-TACT (1-866-763-8228) or visit [www.medisense.com](http://www.medisense.com).